Article info

Download PDFPDF

Original article
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

Authors

  1. Correspondence to Dr David G Warnock, Room 614 ZRB, UAB, 1720 2nd Avenue South, Birmingham, AL 34294-0007, USA; dwarnock{at}uab.edu
View Full Text

Citation

Warnock DG, Thomas CP, Vujkovac B, et al
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

Publication history

  • Received August 22, 2015
  • Accepted September 25, 2015
  • First published October 21, 2015.
Online issue publication 
November 23, 2015

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.